Treatment-cycle-resolved peripheral blood T-cell GP73 dynamics are associated with clinical benefit during PD-1/PD-L1 inhibitor-based therapy in NSCLC.
A blood test measuring immune cell changes during cancer immunotherapy may help doctors know in real-time whether treatment is working, without invasive biopsies.
Prospective flow cytometry study characterizes T-cell GP73 as a treatment-cycle-resolved peripheral blood biomarker for PD-1/PD-L1 inhibitor response in NSCLC, showing between-cycle dynamics can discriminate clinical benefit with AUC >0.86. GP73 offers a potentially actionable, minimally invasive alternative to serial tissue biopsy for real-time immunotherapy monitoring, warranting prospective validation.
What the study was
- Study design
- Prospective longitudinal observational study
- Category
- Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- Maturity
- Exploratory
- Journal
- Lung Cancer
Why it surfaced
Novel peripheral blood biomarker with cycle-resolved dynamics in ICI-treated NSCLC; Chinese PLA General Hospital / Shandong Second Medical University; published in Lung Cancer; sample size n=76 limits generalizability; independent validation needed before clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.